Basics CytomX Therapeutics, Inc. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform. IPO Date: October 8, 2015 Sector: Healthcare Industry: Biotech Market Cap: $669.27M Activated in VL: True Average Daily Range Avg Daily Range: $0.24 | 3.02% Avg Daily Range (30 D): $0.15 | 3.91% Avg Daily Range (90 D): $0.12 | 4.19% Institutional Daily Volume Avg Daily Volume: .89M Avg Daily Volume (30 D): 2.93M Avg Daily Volume (90 D): 3.29M Trade Size Avg Trade Size (Sh.): 191 Avg Trade Size (Sh.) (30 D): 171 Avg Trade Size (Sh.) (90 D): 235 Institutional Trades Total Inst.Trades: 929 Avg Inst. Trade: $1.4M Avg Inst. Trade (30 D): $1.17M Avg Inst. Trade (90 D): $1.03M Avg Inst. Trade Volume: .2M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.57M Avg Closing Trade (30 D): $1.13M Avg Closing Trade (90 D): $.99M Avg Closing Volume: 187.01K     News Nov 13, 2025 @ 1:00 PM CytomX Therapeutics to Present at the Jefferies Lo... Source: Cytomx Therapeutics Oct 30, 2025 @ 12:00 PM CytomX Therapeutics to Report Third Quarter 2025 F... Source: Cytomx Therapeutics Sep 25, 2025 @ 9:06 PM 12 Health Care Stocks Moving In Thursday's After-M... Source: Benzinga Staff Writer Aug 7, 2025 @ 10:29 PM CytomX (CTMX) Q2 Revenue Drops 26% Source: Na Jul 9, 2025 @ 12:30 PM Breaking Through: Systemic Genetic Medicines for H... Source: Prnewswire Financials   TTM Q3 2025 Q2 2025 Basic EPS Diluted EPS Revenue $ 113.63M $ 5.96M $ 18.66M Gross Profit $ $ $ Net Income / Loss $ 28.02M $ -14.23M $ -.15M Operating Income / Loss $ 23.25M $ -15.77M $ -1.29M Cost of Revenue $ $ $ Net Cash Flow $ -6.39M $ -14.86M $ 10.99M PE Ratio